microRNAs are major components of the eukaryotic post-transcriptional machinery and are frequently deregulated during cancer development. Increasing evidence points to them also as key players in the establishment of drug resistance. In this review, we provide an updated overview of the role of miRNAs in melanoma development and drug resistance and postulate that they are able to drive these processes in concert with deregulation of inflammatory and angiogenic cytokine expression. Notably, we have identified by querying the Cancer Genome Atlas database, a defined set of miRNAs which mostly have an impact on the development of melanoma and have recognized the main downstream pathways controlled by them. Most importantly, these miRNAs, which are down-regulated in metastatic melanomas as compared to primary tumors, are also able to predict prognosis of BRAF-mutated melanoma patients. Finally, we discuss the possibility that a common miRNA signature characterizes not only acquired resistance to MAPKi but also innate resistance to anti-PD-1 immunotherapy, since these conditions are both associated with alterations of the same pro-angiogenetic and pro-inflammatory pathways.

MicroRNA-driven deregulation of cytokine expression helps development of drug resistance in metastatic melanoma / Fattore, Luigi; Sacconi, Andrea; Mancini, Rita; Ciliberto, Gennaro. - In: CYTOKINE & GROWTH FACTOR REVIEWS. - ISSN 1359-6101. - ELETTRONICO. - 36:Aug.(2017), pp. 39-48. [10.1016/j.cytogfr.2017.05.003]

MicroRNA-driven deregulation of cytokine expression helps development of drug resistance in metastatic melanoma

FATTORE, LUIGI;MANCINI, RITA;
2017

Abstract

microRNAs are major components of the eukaryotic post-transcriptional machinery and are frequently deregulated during cancer development. Increasing evidence points to them also as key players in the establishment of drug resistance. In this review, we provide an updated overview of the role of miRNAs in melanoma development and drug resistance and postulate that they are able to drive these processes in concert with deregulation of inflammatory and angiogenic cytokine expression. Notably, we have identified by querying the Cancer Genome Atlas database, a defined set of miRNAs which mostly have an impact on the development of melanoma and have recognized the main downstream pathways controlled by them. Most importantly, these miRNAs, which are down-regulated in metastatic melanomas as compared to primary tumors, are also able to predict prognosis of BRAF-mutated melanoma patients. Finally, we discuss the possibility that a common miRNA signature characterizes not only acquired resistance to MAPKi but also innate resistance to anti-PD-1 immunotherapy, since these conditions are both associated with alterations of the same pro-angiogenetic and pro-inflammatory pathways.
2017
cytokines; immunotherapy; melanoma; mirna; targeted therapies; immunology and allergy; endocrinology, diabetes and metabolism; immunology; biochemistry, genetics and molecular biology (all)
01 Pubblicazione su rivista::01a Articolo in rivista
MicroRNA-driven deregulation of cytokine expression helps development of drug resistance in metastatic melanoma / Fattore, Luigi; Sacconi, Andrea; Mancini, Rita; Ciliberto, Gennaro. - In: CYTOKINE & GROWTH FACTOR REVIEWS. - ISSN 1359-6101. - ELETTRONICO. - 36:Aug.(2017), pp. 39-48. [10.1016/j.cytogfr.2017.05.003]
File allegati a questo prodotto
File Dimensione Formato  
Fattore_MicroRNA-driven_2017.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 2.41 MB
Formato Adobe PDF
2.41 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/985090
Citazioni
  • ???jsp.display-item.citation.pmc??? 17
  • Scopus 25
  • ???jsp.display-item.citation.isi??? 25
social impact